As we discussed above, in the IMbrave150 phase III clinical trial for advanced-stage HCC patients, the combination of the anti–PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab demonstrated an objective response rate of 36% (8). This evidence concerns the gene VEGFA and hepatocellular carcinoma.